Stoke Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $1,402 | $10,632 | $13,817 | $158,569 |
Gross Profit | 347 | 9,643 | 13,817 | 158,569 |
EBITDA | -60,384 | -38,633 | -26,854 | 111,717 |
EBIT | -61,439 | -39,622 | -27,300 | 111,240 |
Net Income | -57,934 | -38,347 | -23,483 | 112,879 |
Net Change In Cash | 1,402 | 10,632 | 13,817 | 158,569 |
Free Cash Flow | -30,686 | -30,498 | -25,576 | 131,675 |
Cash | 84,220 | 83,394 | 101,472 | 274,817 |
Basic Shares | 58,389 | 58,611 | 58,353 | 59,398 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $184,420 | $36,555 | $8,780 | $12,405 |
Gross Profit | 184,420 | 36,555 | 8,780 | 12,405 |
EBITDA | -18,820 | -99,195 | -112,304 | -102,810 |
EBIT | -20,590 | -101,372 | -114,773 | -104,356 |
Net Income | -6,885 | -88,981 | -104,699 | -93,110 |
Net Change In Cash | 184,420 | 36,555 | 8,780 | 12,405 |
Cost of Revenue | -31,339 | |||
Free Cash Flow | 44,915 | -87,054 | -82,683 | -35,828 |
Cash | 84,220 | 127,983 | 191,442 | 113,556 |
Basic Shares | 59,219 | 54,008 | 43,994 | 38,897 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.97 |
2025-09-30 | -$0.65 |
2025-06-30 | -$0.40 |
